Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Inhibrx's cash to debt ratio for the quarter that ended in Dec. 2023 was 1.32.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Inhibrx could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.
The historical rank and industry rank for Inhibrx's Cash-to-Debt or its related term are showing as below:
INBX'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.22 Med: 1.32 Max: 3.44
Current: 1.32
During the past 7 years, Inhibrx's highest Cash to Debt Ratio was 3.44. The lowest was 0.22. And the median was 1.32.
Inhibrx Cash-to-Debt Historical Data
The historical data trend for Inhibrx's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
|
Inhibrx Annual Data
|
|
Trend |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Cash-to-Debt |
|
|
|
0.28 |
3.44 |
1.70 |
1.32 |
1.32 |
|
Inhibrx Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Cash-to-Debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1.32 |
1.13 |
0.92 |
1.61 |
1.32 |
Competitive Comparison
For the Biotechnology subindustry, Inhibrx's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inhibrx Cash-to-Debt Distribution
For the Biotechnology industry and Healthcare sector, Inhibrx's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Inhibrx's Cash-to-Debt falls into.
Inhibrx Cash-to-Debt Calculation
This is the ratio of a company's
Cash, Cash Equivalents, Marketable Securities
to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.
Inhibrx's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:
Inhibrx's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inhibrx (Inhibrx) Business Description
Traded in Other Exchanges
N/A
Address
11025 N. Torrey Pines Road, Suite 200, La Jolla, CA, USA, 92037
Inhibrx Inc is a clinical-stage biotechnology company focused on developing a pipeline of novel biologic therapeutic candidates. It combines an understanding of target biology with protein engineering, proprietary discovery technologies, and an integrative approach to research and development to design differentiated therapeutic candidates. The company has four programs in clinical trials, of which three of the programs are for the treatment of various cancers, and one for the treatment of Alpha-1 Antitrypsin Deficiency.
Executives
| Ole Andreas Halvorsen |
10 percent owner |
600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901 |
| Viking Global Opportunities Parent Gp Llc |
10 percent owner |
600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901 |
| Rose Sharon Shabet |
10 percent owner |
600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901 |
| Viking Global Opportunities Gp Llc |
10 percent owner |
55 RAILROAD AVENUE, GREENWICH CT 06830 |
| Viking Global Investors Lp |
10 percent owner |
600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901 |
| David C. Ott |
10 percent owner |
600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901 |
| Mark Lappe |
director, 10 percent owner, officer: Chief Executive Officer |
11622 EL CAMINO REAL, SUITE 100, SAN DIEGO CA 92130 |
| Brendan P. Eckelman |
director, 10 percent owner, officer: Chief Scientific Officer |
C/O INHIBRX, INC., 11025 N. TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037 |
| Jon Faiz Kayyem |
director, 10 percent owner |
5964 LA PLACE COURT, CARLSBAD CA 92008 |
| Dragsa 50 Llc |
10 percent owner |
55 RAILROAD AVENUE, GREENWICH CT 06830 |
| Viking Global Opportunities Portfolio Gp Llc |
10 percent owner |
600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901 |
| Viking Global Opportunities Illiquid Investments Sub-master Lp |
10 percent owner |
600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901 |
| Kristiina Md Vuori |
director |
C/O WEBMD HEALTH CORP., 111 EIGHTH AVENUE, NEW YORK NY 10011 |
| Klaus W. Wagner |
officer: Chief Medical Officer |
C/O INHIBRX, INC., 11025 N. TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037 |
| Kimberly Manhard |
director |
C/O HERON THERAPEUTICS, INC, 4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO CA 92121 |
Inhibrx (Inhibrx) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
INBX has been successfully added to your